Allarity Therapeutics, Inc. (ALLR)
NASDAQ: ALLR · Real-Time Price · USD
0.8410
-0.0342 (-3.91%)
At close: Nov 17, 2026, 4:00 PM EST
0.922949
+0.0819 (9.74%)
After-hours: Nov 17, 2026, 4:17 PM EST
Allarity Therapeutics Revenue
Allarity Therapeutics had revenue of $5.00K in the quarter ending September 30, 2026. This brings the company's total for the last twelve months to $350.00K. In the year 2025, Allarity Therapeutics had annual revenue of $320.00K. That makes Allarity Therapeutics the 44,961st largest company in the world by revenue and 6,456th in the United States.
Revenue (ttm)
$350.00K
Revenue Growth
n/a
P/S Ratio
38.23
Revenue / Employee
$43,750
Employees
8
Market Cap
13.38M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 320.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Marker Therapeutics | 3.55M |
| Seres Therapeutics | 2.13M |
| Neuphoria Therapeutics | 1.17M |
| aTyr Pharma | 190.00K |
| Fractyl Health | 3.00K |
ALLR News
- 1 day ago - Allarity expands Phase 2 stenoparib trial to three ovarian cancer cohorts - TheFly
- 1 day ago - Allarity Therapeutics Expands Phase 2 Stenoparib Trial to Three Ovarian Cancer Patient Cohorts - GlobeNewsWire
- 4 days ago - Allarity Therapeutics Reports Third Quarter 2026 Results and Provides Full Year 2026 Financial Guidance - GlobeNewsWire
- 18 days ago - Allarity secures first commercial agreement under CLIA strategy - TheFly
- 18 days ago - Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue - GlobeNewsWire
- 6 weeks ago - Allarity updates on recent advances in Drug Response Predictor technology - TheFly
- 6 weeks ago - Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib's Clinical Development - GlobeNewsWire
- 7 weeks ago - Allarity expands lab capabilities to include proteomics, cell line research - TheFly